Search Result

Results for "

CR1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CX3CR1 (11) 5-HT Receptor (1) Apoptosis (2) Calcium Channel (2) CCR (4) CXCR (2) Drug Isomer (1) Endogenous Metabolite (1) Eukaryotic Initiation Factor (eIF) (1) HMG Family (2) Keap1-Nrf2 (2) Ligands for Target Protein for PROTAC (1) mRNA (1) Mucin (1) NF-κB (2) NO Synthase (2) NOD-like Receptor (NLR) (2) PCSK9 (2) Reference Standards (4) Small Interfering RNA (siRNA) (7) Trace Amine-associated Receptor (TAAR) (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (5) Endocrinology (9) Inflammation/Immunology (13) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	Chemokine & Receptors (1) Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (2) mRNA (1) Human Pre-designed siRNA Sets (4) siRNAs (7)

Inhibitors & Agonists

Fluorescent Dyes

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: CX3CR1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13848

Rugocrixan Maximum Cited Publications 21 Publications Verification AZD8797; KAND567	CX3CR1 CXCR	Inflammation/Immunology Endocrinology Cancer
AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human *CX3CR1* receptor; antagonizes CX3CR1 and CXCR2 with K_is of 3.9 and 2800 nM, respectively ^[1].

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates *Nrf2/HO-1, HMGB1/NF-κB* and *Fractalkine/CX3CR1*. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation ^[1] .

HY-123918

JMS-17-2 15+ Cited Publications	CX3CR1	Endocrinology Cancer
JMS-17-2 is a potent and selective *CX3CR1* antagonist with an IC₅₀ of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells ^[1].

HY-W074890

Palmitoylglycine 1 Publications Verification N-palmitoyl glycine	Calcium Channel NO Synthase	Neurological Disease Inflammation/Immunology
Palmitoylglycine (N-palmitoyl glycine), an endogenous lipid that acts as a modulator of calcium influx and nitric oxide () production in sensory neurons. Palmitoylglycine is linked to an increased risk of Background Brugada syndrome (BrS) and interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA ^[1] .

HY-160421

TREM2-IN-1	Apoptosis	Inflammation/Immunology Cancer
TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate. TREM2-IN-1 can relieves immunosuppressive tumor microenvironment and enhancing chemical anticancer efficiency. TREM2-IN-1 deters the tumor growth in mice models bearing MC38 colorectal tumor by reducing the number of CD206 ⁺ and CX₃CR1 ⁺ immunosuppressive macrophages. TREM2-IN-1 also promotes the expansion and infiltration of immunostimulatory dendritic, cytotoxic T and natural killer cells ^[1].

HY-15724

Vercirnon 3 Publications Verification GSK-1605786; CCX282-B; Traficet-EN	CCR Ligands for Target Protein for PROTAC	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 μM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively ^[1].

HY-136453

CR-1-31-B 10+ Cited Publications	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor. CR-1-31-B exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis. CR-1-31-B perturbs association of Plasmodium falciparum eIF4A (PfeIF4A) with RNA. CR-1-31-B induces apoptosis of neuroblastoma and gallbladder cancer cells ^[1] .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates *Nrf2/HO-1, HMGB1/NF-κB* and *Fractalkine/CX3CR1*. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation ^[1] .

HY-107456

E6130 2 Publications Verification	CX3CR1	Inflammation/Immunology Endocrinology
E6130 is an orally active and highly selective *CX3CR1* modulator, that may be effective for treatment of inflammatory bowel disease.

HY-175746

AZD0233	CX3CR1	Cardiovascular Disease
AZD0233 is an orally active *CX3CR1* antagonist. AZD0233 modulates the CX3CR1/CX3CL1 signaling axis via immunomodulatory effects. AZD0233 has improved physicochemical properties, metabolic stability, low toxicity and CYP inhibition. AZD0233 improves cardiac function and reduces macrophages and fibrotic scar in mice model of dilated cardiomyopathy. AZD0233 can be used for cardiovascular diseases like dilated cardiomyopathy research ^[1].

HY-P99404

Quetmolimab E6011	CXCR	Inflammation/Immunology Cancer
Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of *CX3CR1*-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis ^[1].

HY-15724A

Vercirnon sodium 3 Publications Verification GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium	CCR	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively ^[1].

HY-RS03131

CR1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CR1 Human Pre-designed siRNA Set A CR1 Human Pre-designed siRNA Set A

HY-W074890R

Palmitoylglycine (Standard) N-palmitoyl glycine (Standard)	Reference Standards Calcium Channel NO Synthase	Neurological Disease Inflammation/Immunology
Palmitoylglycine (Standard) is the analytical standard of Palmitoylglycine. This product is intended for research and analytical applications. Palmitoylglycine (N-palmitoyl glycine), an endogenous lipid that acts as a modulator of calcium influx and nitric oxide () production in sensory neurons. Palmitoylglycine is linked to an increased risk of Background Brugada syndrome (BrS) and interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA[1][2][3].

HY-RS03380

Cx3cr1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cx3cr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cx3cr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cx3cr1 Mouse Pre-designed siRNA Set A Cx3cr1 Mouse Pre-designed siRNA Set A

HY-P2969

Complement factor I	Endogenous Metabolite	Metabolic Disease
Complement factor I is a serine protease that downregulates complement activity in the fluid phase and/or on cell surfaces in conjunction with one of its cofactors, factor H (FH), complement receptor 1 (CR1/CD35), C4 binding protein (C4BP) or membrane cofactor protein (MCP/CD46) ^[1].

HY-168975

Fosrugocrixan	CX3CR1	Inflammation/Immunology
Fosrugocrixan is an antagonist for CX3C chemokine receptor 1 (CX3CR1) that exhibits anti-inflammatory activity ^[1].

HY-136453A

CR-1-30-B	Mucin Drug Isomer	Cancer
CR-1-30-B is an inactive enantiomer of CR-1-31-B. CR-1-30-B, as a control, is inactive against eIF4A and has no apparent effect on the induction of MUC1-C translation ^[1].

HY-RS03132

CR1L Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CR1L Human Pre-designed siRNA Set A contains three designed siRNAs for CR1L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CR1L Human Pre-designed siRNA Set A CR1L Human Pre-designed siRNA Set A

HY-RS03379

CX3CR1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CX3CR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CX3CR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CX3CR1 Human Pre-designed siRNA Set A CX3CR1 Human Pre-designed siRNA Set A

HY-RS03381

Cx3cr1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cx3cr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cx3cr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cx3cr1 Rat Pre-designed siRNA Set A Cx3cr1 Rat Pre-designed siRNA Set A

HY-D3080

*CR-1*

HY-RS14330

TDGF1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TDGF1 Human Pre-designed siRNA Set A contains three designed siRNAs for TDGF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TDGF1 Human Pre-designed siRNA Set A TDGF1 Human Pre-designed siRNA Set A

HY-173451

TAAR1/5-H-2CR agonist-1	Trace Amine-associated Receptor (TAAR) 5-HT Receptor	Neurological Disease
TAAR1/5-H-2CR agonist-1 (compound 21b) is a *TAAR1* and 5-HT_2CR dual agonist with EC₅₀s of 0.022 and 0.246 μM, respectively. TAAR1/5-H-2CR agonist-1 can used in the study of schizophrenia and Alzheimer's Disease ^[1].

HY-123918A

JMS-17-2 hydrochloride	CX3CR1	Endocrinology Cancer
JMS-17-2 hydrochloride is a potent and selective *CX3CR1* antagonist with an IC₅₀ of 0.32 nM. JMS-17-2 hydrochloride impairs metastatic seeding and colonization of breast cancer cells ^[1].

HY-15724R

Vercirnon (Standard) GSK-1605786 (Standard); CCX282-B (Standard); Traficet-EN (Standard)	CCR Reference Standards	Inflammation/Immunology Endocrinology
Vercirnon (Standard) is the analytical standard of Vercirnon. This product is intended for research and analytical applications. Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively ^[1].

HY-15724AR

Vercirnon sodium (Standard) GSK-1605786 sodium (Standard); CCX282-B sodium (Standard); Traficet-EN sodium (Standard)	CCR Reference Standards	Inflammation/Immunology Endocrinology
Vercirnon (sodium) (Standard) is the analytical standard of Vercirnon (sodium). This product is intended for research and analytical applications. Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively ^[1].

HY-181016

CX3CR1-IN-2	CX3CR1	Cardiovascular Disease
CX3CR1-IN-2 (Compound 77) is a CX3CR1 inhibitor with an IC₅₀ of 0.04 μM. CX3CR1-IN-2 can block the interaction between CX3CR1 and its ligand fractalkine (CX3CL1). CX3CR1-IN-2 can be used for research of cardiovascular disease, such as heart failure and cardiomyopathy ^[1].

HY-179653

CX3CR1-IN-1	CX3CR1	Cardiovascular Disease
CX3CR1-IN-1 (Compound 24) is a *CX3CR1* inhibitor with an IC₅₀ of 9 nM. CX3CR1-IN-1 can be used for the study of cardiovascular diseases ^[1].

HY-174731

Human CX3CR1 mRNA	mRNA	Inflammation/Immunology
Human CX3CR1 mRNA encodes the human C-X3-C motif chemokine receptor 1 (CX3CR1) protein, a receptor for fractalkine. CX3CR1 is also a coreceptor for HIV-1, and some variations in this gene lead to increased susceptibility to HIV-1 infection and rapid progression to AIDS.

HY-RS18588

Cr2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cr2 Mouse Pre-designed siRNA Set A Cr2 Mouse Pre-designed siRNA Set A

HY-107456R

E6130 (Standard)	Reference Standards CX3CR1	Inflammation/Immunology Endocrinology
E6130 (Standard) is the analytical standard of E6130 (HY-107456). This product is intended for research and analytical applications. E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.

Cat. No.	Product Name	Target	Research Area	Image

HY-P9928

Alirocumab 1 Publications Verification REGN 727; SAR 236553	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates *Nrf2/HO-1, HMGB1/NF-κB* and *Fractalkine/CX3CR1*. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation ^[1] .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1	Cardiovascular Disease Cancer
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates *Nrf2/HO-1, HMGB1/NF-κB* and *Fractalkine/CX3CR1*. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation ^[1] .

HY-P99404

Quetmolimab E6011	CXCR	Inflammation/Immunology Cancer
Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of *CX3CR1*-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis ^[1].

Palmitoylglycine 1 Publications Verification N-palmitoyl glycine	Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Calcium Channel NO Synthase
Palmitoylglycine (N-palmitoyl glycine), an endogenous lipid that acts as a modulator of calcium influx and nitric oxide () production in sensory neurons. Palmitoylglycine is linked to an increased risk of Background Brugada syndrome (BrS) and interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA ^[1] .

Palmitoylglycine (Standard) N-palmitoyl glycine (Standard)	Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Calcium Channel NO Synthase
Palmitoylglycine (Standard) is the analytical standard of Palmitoylglycine. This product is intended for research and analytical applications. Palmitoylglycine (N-palmitoyl glycine), an endogenous lipid that acts as a modulator of calcium influx and nitric oxide () production in sensory neurons. Palmitoylglycine is linked to an increased risk of Background Brugada syndrome (BrS) and interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA[1][2][3].

Species:	Human (4) Mouse (1)
Tag:	His (2) Tag Free (1) GST (1) Fc (1)
Source:	HEK293 (3) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P700481

	TDGF1 Protein, Human (GST) CRipto-1 growth factor ; CRGFEpidermal growth factor-like CRipto protein CR1	Human	E. coli
	The TDGF1 protein is a GPI-anchored cell membrane protein involved in Nodal signaling. TDGF1 Protein, Human (GST) is the recombinant human-derived TDGF1 protein, expressed by E. coli , with N-GST labeled tag.

HY-P71112

	TDGF1 Protein, Human (HEK293, Fc) Teratocarcinoma-derived growth factor 1; CRipto-1 growth factor; CRGF; Epidermal growth factor-like CRipto protein CR1; TDGF1; CRIPTO	Human	HEK293
	The TDGF1 protein is a GPI-anchored cell membrane protein involved in Nodal signaling. TDGF1 Protein, Human (HEK293, Fc) is the recombinant human-derived TDGF1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P703895

	TDGF1 Protein, Human (HEK293, His) Teratocarcinoma-derived growth factor 1; CRipto-1 growth factor; CRGF; Epidermal growth factor-like CRipto protein CR1; TDGF1; CRIPTO	Human	HEK293
	TDGF1 Protein, Human (HEK293, His) is the recombinant human-derived TDGF1 protein, expressed by HEK293, with C-His tag.

HY-P702506

	TDGF1 Protein, Mouse (HEK293, His) CFC-2; CR; CRipto; CRipto-1 growth factor; CRipto-1; CRIPTOCRGF; Epidermal growth factor-like CRipto protein CR1; TDGF1; TDGF-1; teratocarcinoma-derived growth factor 1	Mouse	HEK293
	TDGF1, a GPI-anchored protein, participates in Nodal signaling pathways as a coreceptor in cis. Shedding by Tmem8a dynamically regulates Nodal signaling, releasing soluble TDGF1. This shedding mechanism modulates the Nodal pathway and suggests a role in determining the fate of epiblastic cells, particularly in mesoderm formation. TDGF1 also interacts with ACVR1B, emphasizing its importance in cellular responses. TDGF1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived TDGF1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P71912

	RANK/TNFRSF11A Protein, Human CD 265; CD265; FEO; LOH18CR1; Loss of heterozygosity 18 chromosomal region 1; mRANK; ODFR; OFE; OPTB7; Osteoclast differentiation factor receptor; OSTS; Paget disease of bone 2; PDB 2; PDB2; RANK; Receptor activator of NF KB; Receptor activator of NF-KB; receptor activator of nuclear factor kappa B; TNF receptor superfamily member 11a; TNFRSF11A; TNR11_HUMAN; TRANCER; Tumor neCRosis factor receptor superfamily member 11a NFKB activator; Tumor neCRosis factor receptor superfamily member 11a activator of NFKB; Tumor neCRosis factor receptor superfamily member 11A	Human	E. coli
	RANK/TNFRSF11A protein is the receptor of TNFSF11/RANKL and is critical for RANKL-induced osteoclastogenesis. It interacts with EEIG1 to promote osteoclast formation by promoting NFATC1 transcription and activating PLCG2. RANK/TNFRSF11A Protein, Human is the recombinant human-derived RANK/TNFRSF11A protein, expressed by E. coli , with tag free.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (8) Rabbit (5)
Reactivity:	Human (13) Rat (3) Mouse (5)
Application:	IHC-P (5) ICC/IF (7) IP (2) WB (9) FC (5) ELISA (6)
Isotype:	IgG (5) IgG1 (3) IgG2a (4)
Conjugation:	Non-conjugated (13)
Clonality:	Monoclonal (9) Recombinant (3)
Modification:	Unmodified (9)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85894

	CD35 Antibody (YA5586) C3 binding protein; C3b/C4b receptor; C3BR; C4BR; CD 35; CD35; CD35 antigen; complement component; 3b/4b; receptor 1; Knops blood group; complement component; 3b/4b; receptor 1 including Knops blood group system; Complement component receptor 1; Complement receptor 1; Complement receptor type 1; CR 1; CR1; CR1_HUMAN; KN; Knops blood group antigen	IHC-P, WB, ICC/IF, ELISA	Human
	CD35 Antibody (YA5586) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD35.

HY-P85107

	Cripto1/CRIPTO Antibody (YA4799) TDGF1; CRIPTO; Teratocarcinoma-derived growth factor 1; CRipto-1 growth factor; CRGF; Epidermal growth factor-like CRipto protein CR1	WB, ELISA	Human
	Cripto1/CRIPTO Antibody (YA4799) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Cripto1/CRIPTO.

HY-P88948

	LOH12CR1 Antibody (YA8632) LOH1CR12	ICC/IF	Human
	LOH12CR1 Antibody (YA8632) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to LOH12CR1.

HY-P88948A

	LOH12CR1 Antibody (YA8632)(PBS only) LOH1CR12	ICC/IF	Human
	LOH12CR1 Antibody (YA8632) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to LOH12CR1.

HY-P87493

	ADX/FDX1 Antibody (YA7180) Adrenodoxin, ADX, Ferredoxin-1,LOH11CR1D,FDX, FDX1	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	ADX/FDX1 Antibody (YA7180) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ADX/FDX1.

HY-P84354

	CX3CR1 Antibody (YA4051) V28; CCRL1; GPR13; CMKDR1; GPRV28; CMKBRL1	ICC/IF, FC, ELISA	Human
	CX3CR1 Antibody (YA4051) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CX3CR1.

HY-P84354A

	CX3CR1 Antibody (YA4051)(PBS only) V28; CCRL1; GPR13; CMKDR1; GPRV28; CMKBRL1	ICC/IF, FC, ELISA	Human
	CX3CR1 Antibody (YA4051) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CX3CR1.

HY-P84907

	RANK Antibody (YA4604) FEO; OFE; ODFR; OSTS; PDB2; RANK; CD265; OPTB7; TRANCER; LOH18CR1; TRANCE-R	WB, FC, ELISA	Human, Mouse, Rat
	RANK Antibody (YA4604) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to RANK.

HY-P82260

	ADX/FDX1 Antibody (YA2005) 1 Publications Verification ADX; FDX; LOH11CR1D; FDX1; Ferredoxin 1 antibody; Adrenal ferredoxin antibody	WB, IHC-P, IP	Human, Mouse
	ADX/FDX1 Antibody (YA2005) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ADX.

HY-P81862

	RANK Antibody (YA1607) CD265; FEO; LOH18CR1; mRANK; ODFR; OFE; OPTB7; OSTS; PDB2; RANK; TNFRSF11A; TRANCER	WB	Human
	RANK Antibody (YA1607) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RANK.

HY-P84907A

	RANK Antibody (YA4604)(PBS only) FEO; OFE; ODFR; OSTS; PDB2; RANK; CD265; OPTB7; TRANCER; LOH18CR1; TRANCE-R	WB, FC, ELISA	Human, Mouse, Rat
	RANK Antibody (YA4604) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to RANK.

HY-P82260A

	ADX/FDX1 Antibody (YA2005)(PBS only) ADX; FDX; LOH11CR1D; FDX1; Ferredoxin 1 antibody; Adrenal ferredoxin antibody	WB, IHC-P, IP	Human, Mouse
	ADX/FDX1 Antibody (YA2005) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ADX.

HY-P86770

	ALS2CR1 Antibody (YA6463) ALS2CR1 antibody; Amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 1 antibody; Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 1 protein antibody; CALS-7 antibody; MDS015 antibody; Ngg1 interacting factor 3-like 1 antibody; NIF3 (Ngg1 interacting factor 3, S.pombe homolog)-like 1 antibody; NIF3 NGG1 interacting factor 3-like 1 (S. pombe) antibody; NIF3 NGG1 interacting factor 3-like 1 antibody; NIF3-like protein 1 antibody; ALS2CR1 antibody; Amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 1 antibody; Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 1 protein antibody; CALS-7 antibody; MDS015 antibody; Ngg1 interacting factor 3-like 1 antibody; NIF3 (Ngg1 interacting factor 3, S.pombe homolog)-like 1 antibody; NIF3 NGG1 interacting factor 3-like 1 (S. pombe) antibody; NIF3 NGG1 interacting factor 3-like 1 antibody; NIF3-like protein 1 antibody; NIF3L_HUMAN antibody; Nif3l1 antibody; OTTHUMP00000206190 antibody; OTTHUMP00000206191 antibody; OTTHUMP00000206192 antibody;	WB, ICC/IF, IHC-P, FC	Human
	ALS2CR1 Antibody (YA6463) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ALS2CR1.